| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2169 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1690 | 2017 |
| Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. F Oberhammer, JW Wilson, C Dive, ID Morris, JA Hickman, AE Wakeling, ... The EMBO journal 12 (9), 3679-3684, 1993 | 1496 | 1993 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1154 | 2017 |
| Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ... Journal of clinical oncology 29 (12), 1556-1563, 2011 | 1049 | 2011 |
| Imaging biomarker roadmap for cancer studies JPB O'connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1030 | 2017 |
| Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ... Journal of clinical oncology 30 (5), 525-532, 2012 | 970 | 2012 |
| Progress and prospects of early detection in lung cancer S Blandin Knight, PA Crosbie, H Balata, J Chudziak, T Hussell, C Dive Open biology 7 (9), 170070, 2017 | 843 | 2017 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 831 | 2019 |
| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ... Nature medicine 20 (8), 897-903, 2014 | 787 | 2014 |
| Biological mechanisms linking obesity and cancer risk: new perspectives DL Roberts, C Dive, AG Renehan Annual review of medicine 61, 301-316, 2010 | 744 | 2010 |
| Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry C Dive, CD Gregory, DJ Phipps, DL Evans, AE Milner, AH Wyllie Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1133 (3), 275-285, 1992 | 714 | 1992 |
| Molecular analysis of circulating tumour cells—biology and biomarkers MG Krebs, RL Metcalf, L Carter, G Brady, FH Blackhall, C Dive Nature reviews Clinical oncology 11 (3), 129-144, 2014 | 688 | 2014 |
| Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis CD Gregory, C Dive, S Henderson, CA Smith, GT Williams, J Gordon, ... Nature 349 (6310), 612-614, 1991 | 652 | 1991 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors L Gandhi, DR Camidge, M Ribeiro de Oliveira, P Bonomi, D Gandara, ... Journal of clinical oncology 29 (7), 909-916, 2011 | 650 | 2011 |
| Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis GJ Griffiths, L Dubrez, CP Morgan, NA Jones, J Whitehouse, BM Corfe, ... The Journal of cell biology 144 (5), 903-914, 1999 | 650 | 1999 |
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, ... Clinical Cancer Research 18 (11), 3163-3169, 2012 | 602 | 2012 |
| Drug-target interactions: only the first step in the commitment to a programmed cell death? C Dive, JA Hickman British journal of cancer 64 (1), 192-196, 1991 | 595 | 1991 |
| Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches MG Krebs, JM Hou, R Sloane, L Lancashire, L Priest, D Nonaka, TH Ward, ... Journal of thoracic oncology 7 (2), 306-315, 2012 | 548 | 2012 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 537 | 2018 |
